What alternative treatments are available for COVID-19 besides Paxlovid?

Alternative COVID-19 Treatments Besides Paxlovid

For symptomatic patients with confirmed mild to moderate COVID-19 who are within 5 days of symptom onset and at high risk for severe disease, consider molnupiravir as the primary alternative to Paxlovid, or remdesivir if parenteral administration is feasible. 1

High-Risk Patient Criteria

You qualify as high-risk if you have:

• Immunodeficiency syndromes, solid organ transplant on immunosuppressants, or autoimmune disease on immunosuppressants
• Diabetes, overweight (BMI >25), chronic lung disease, chronic kidney disease
• Current smoker, cardiovascular disease, hypertension, sickle cell disease
• Active cancer or age ≥60 years (regardless of comorbidities) 2, 3

Recommended Alternatives (in order of preference)

1. Molnupiravir (First-line alternative)

• Use within 5 days of symptom onset in high-risk patients with mild to moderate COVID-19
• Oral administration makes it practical when nirmatrelvir/ritonavir is contraindicated or unavailable
• Supported by American College of Physicians 2024 guidelines 1
• No significant drug-drug interactions like Paxlovid has

2. Remdesivir (Second-line alternative)

• Effective antiviral option but requires parenteral (IV) administration
• Most promising among repurposed drugs based on clinical evidence 4
• Practical limitation: requires healthcare facility access for infusion
• Consider when oral options are contraindicated and IV access is available 2, 5

3. Anti-inflammatory agents (for severe/critical disease only)

If disease progresses beyond mild-moderate:

• Dexamethasone (corticosteroid) - effective in late COVID-19 5
• Tocilizumab or Sarilumab (IL-6 inhibitors) - for COVID-19 pneumonia 4, 5
• Baricitinib (JAK inhibitor) - can be combined with corticosteroids in severe cases 2, 5

Critical Timing Window

All antiviral treatments must be initiated within 5 days of symptom onset to achieve meaningful reduction in hospitalization and mortality 1, 3, 6. After this window, antivirals show minimal benefit, and treatment shifts to anti-inflammatory strategies if disease worsens.

What NOT to Use

Do not use ivermectin - explicitly not supported by current guidelines, showed no significant outcomes 1, 4

Do not use sotrovimab - monoclonal antibodies show limited or no efficacy against current Omicron variants 1, 5

Important Caveats

• The absolute benefit of treatment is greatest in patients with highest baseline mortality risk 2
• Drug availability varies significantly, particularly in low and middle-income countries 2
• Paxlovid remains superior when no contraindications exist (86% relative risk reduction in hospitalization/death) 3
• Consider drug-drug interactions carefully - this is where molnupiravir has advantage over nirmatrelvir/ritonavir 3

Treatment Selection Algorithm

1. Confirm eligibility: Mild-moderate COVID-19 + high-risk criteria + within 5 days of symptoms
2. First choice: Nirmatrelvir/ritonavir (Paxlovid) if no contraindications
3. If Paxlovid contraindicated/unavailable: Molnupiravir (oral)
4. If oral agents unsuitable: Remdesivir (IV)
5. If disease progresses to severe: Add dexamethasone ± tocilizumab/baricitinib

The 2026 IDSA guideline update reinforces these antiviral options with updated dosing algorithms 6, and recent pharmacokinetic studies have even established safe dosing for patients with severe renal impairment 7.